http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Jaemin Kim(Jaemin Kim),Hyoung Seok Kim(Hyoung Seok Kim),Su Jin Yoo(Su Jin Yoo),Moon Jung Choi(Moon Jung Choi),Youngju Lew(Youngju Lew),Jong Woo Kim(Jong Woo Kim),Han Joo Cho(Han Joo Cho) 대한안과학회 2022 Korean Journal of Ophthalmology Vol.36 No.5
Purpose: To determine the efficacy of immediate pars plana vitrectomy as the primary treatment for acute endophthalmitis in patients with a visual acuity (VA) of hand motion (HM) or better. Methods: A total of 149 patients who were referred to a single center for acute endophthalmitis after cataract surgery over the 13-year study period were retrospectively analyzed. Only patients presenting with a VA of at least HM were included. Patients were initially treated with either primary vitrectomy or intravitreal antibiotic injection alone, and their visual outcomes and reintervention rates after initial treatment were compared. Results: There was no significant difference in the proportion of good (final VA ≥20 / 40) and poor (VA ≤ counting finger) visual outcomes between the groups. However, subgroup analysis of patients with a VA of HM (92 eyes) showed that the incidence of reintervention (14 of 72 eyes [19.4%] vs. 9 of 20 eyes [45.0%]) and poor visual outcomes (10 of 72 eyes [13.9%] vs. 8 of 20 eyes [40.0%]) were lower after prompt vitrectomy than after intravitreal antibiotic injection alone (p = 0.019 and p = 0.022, respectively). For those with a VA of at least counting finger, no significant difference was observed between the groups. Conclusions: For patients with endophthalmitis presenting with a VA of HM, performing a prompt vitrectomy reduced the incidence of reintervention and poor visual outcomes than the administration of intravitreal antibiotics alone. Our results suggest that primary vitrectomy for patients with endophthalmitis presenting with a VA of HM could be more beneficial than intravitreal antibiotic injection alone.
Obesity and hepatocellular carcinoma in patients receiving entecavir for chronic hepatitis B
( Jaemin Lee ),( Sun Hong Yoo ),( Won Sohn ),( Hyung Woo Kim ),( Yong Sun Choi ),( Jung Ho Won ),( Jin Young Heo ),( Sang Jong Park ),( Young Min Park ) 대한간학회 2016 Clinical and Molecular Hepatology(대한간학회지) Vol.22 No.3
Background/Aims: This study aimed to clarify the effect of obesity on the development of hepatocellular carcinoma (HCC) in chronic hepatitis B (CHB) patients receiving antiviral treatment. Methods: This study applied a retrospective analysis to a historical cohort in Bundang Jesaeng Hospital. In total, 102 CHB patients were treated with entecavir as an initial treatment for CHB and checked for obesity using a body composition analyzer. Hepatic steatosis was measured semiquantitatively using Hamaguchi’s scoring system in ultrasonography. Risk factors for the development of HCC were analyzed, including obesity-related factors (body mass index [BMI], waist circumference [WC], waist-to-hip ratio [WHR], visceral fat area [VFA], and hepatic steatosis). Results: The median follow-up duration of the patients was 45.2 months (interquartile range: 36.0-58.3 months). The cumulative incidence rates of HCC at 1 year, 3 years, and 5 years were 0%, 5.3%, and 9.0%, respectively. Univariable analysis revealed that the risk factors for HCC development were a platelet count of <120,000 /mm² (hazard ratio [HR]=5.21, P=0.031), HBeAg negativity (HR=5.61, P=0.039), and liver cirrhosis (HR=10.26, P=0.031). Multivariable analysis showed that the significant risk factor for HCC development was liver cirrhosis (HR=9.07, P=0.042). However, none of the obesity-related risk factors were significantly associated with HCC: BMI ≥25 kg/m² (HR=0.90, P=0.894), WC ≥90 cm (HR=1.10, P=0.912), WHR ≥0.9 (HR=1.94, P=0.386), VFA ≥100 cm² (HR=1.69, P=0.495), and hepatic steatosis (HR=0.57, P=0.602). Conclusions: HCC development is associated with liver cirrhosis but not obesity-related factors in CHB patients receiving entecavir. (Clin Mol Hepatol 2016;22:339-349)
Obesity and Hepatocellular Carcinoma in Patients Receiving Entecavir for Chronic Hepatitis B
( Jaemin Lee ),( Sun Hong Yoo ),( Sang Jong Park ),( Young Min Park ),( Won Sohn ) 대한간학회 2016 춘·추계 학술대회 (KASL) Vol.2016 No.1
Aims: It is unclear whether or not obesity influences hepatocellular carcinoma (HCC) in chronic hepatitis B (CHB) unlike chronic hepatitis C. This study aimed to clarify the effect of obesity on the development of HCC in CHB patients receiving antiviral treatment. Methods: This study was retrospectively analyzed based on a historical cohort in Bundang Jesaeng Hospital. A total of 102 CHB patients were treated with entecavir as an initial treatment for CHB and checked with body composition analyzer (electrical bioimpedance analysis) for obesity. Hepatic steatosis was measured semi-quantitatively using Hamaguchi’s scoring system in ultrasonography. Risk factors including obesity-related factors (body mass index, waist circumference, waist-to-hip ratio, visceral fat area, and hepatic steatosis) were analyzed for HCC development. Results: The median follow-up duration of the patients was 45.2 (interquartile range: 36.0~58.3) months. The cumulative incidence rates of HCC at 1 year, 3 years, and 5 years were 0%, 5.3%, and 9.0%, respectively. Univariable analysis revealed that the risk factors for HCC development were platelet count <120,000 /mm2 (HR 5.21, p=0.031), HBeAg negativity (HR 5.61, p=0.039), and liver cirrhosis (HR 10.26, p=0.031). Multivariable analysis showed that the significant risk factor for HCC development was liver cirrhosis (HR 9.07, p=0.042). However, none of obesity-related risk factors were significantly associated with HCC: BMI ≥25 kg/m2 (HR 0.90, p=0.894), waist circumference ≥90 cm (HR 1.10, p=0.912), waist-to-hip ratio ≥0.9 (HR 1.94, p=0.386), visceral fat area ≥100 cm2 (HR 1.69, p=0.495), and hepatic steatosis (HR 0.57, p=0.602). Conclusions: HCC development is associated with liver cirrhosis but not obesity-related factors in CHB patients receiving entecavir.
Yoo Wonbeak,Choi Hyunji,Son Young Hoon,Lee Jaemin,Jo Seongyea,Jung Dana,Kim Yeon Jeong,Koh Sang Seok,Yang Yong Ryoul,Kwon Eun-Soo,Lee Kwang-Pyo,노경희,Kim Kyung Won,Ko Yousun,Jun Eunsung,Kim Song Cheol,K 생화학분자생물학회 2021 Experimental and molecular medicine Vol.53 No.-
Cancer cachexia is a highly debilitating condition characterized by weight loss and muscle wasting that contributes significantly to the morbidity and mortality of pancreatic cancer. The factors that induce cachexia in pancreatic cancer are largely unknown. We previously showed that pancreatic adenocarcinoma upregulated factor (PAUF) secreted by pancreatic cancer cells is responsible for tumor growth and metastasis. Here, we analyzed the relation between pancreatic cancer-derived PAUF and cancer cachexia in mice and its clinical significance. Body weight loss and muscle weight loss were significantly higher in mice with Panc-1/PAUF tumors than in those with Panc-1/Mock tumors. Direct administration of rPAUF to muscle recapitulated tumor-induced atrophy, and a PAUF-neutralizing antibody abrogated tumor-induced muscle wasting in Panc-1/PAUF tumor-bearing mice. C2C12 myotubes treated with rPAUF exhibited rapid inactivation of Akt-Foxo3a signaling, resulting in Atrogin1/MAFbx upregulation, myosin heavy chain loss, and muscle atrophy. The neutrophil-to-lymphocyte ratio and body weight loss were significantly higher in pancreatic cancer patients with high PAUF expression than in those with low PAUF expression. Analysis of different pancreatic cancer datasets showed that PAUF expression was significantly higher in the pancreatic cancer group than in the nontumor group. Analysis of The Cancer Genome Atlas data found associations between high PAUF expression or a high DNA copy number and poor overall survival. Our data identified tumor-secreted circulating PAUF as a key factor of cachexia, causing muscle wasting in mice. Neutralizing PAUF may be a useful therapeutic strategy for the treatment of pancreatic cancer-induced cachexia.